open access
Vol 29, No 5 (2022)
Editorial
Submitted: 2022-05-29
Accepted: 2022-06-30
Published online: 2022-09-28
Get Citation
Opioids and oral P2Y12 receptor inhibitors: A drug–drug interaction
1
Affiliations- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
open access
Vol 29, No 5 (2022)
Editorial
Submitted: 2022-05-29
Accepted: 2022-06-30
Published online: 2022-09-28
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Opioids and oral P2Y12 receptor inhibitors: A drug–drug interaction
Journal
Issue
Article type
Editorial
Pages
727-729
Published online
2022-09-28
Page views
3883
Article views/downloads
500
DOI
10.5603/CJ.2022.0082
Pubmed
Bibliographic record
Cardiol J 2022;29(5):727-729.
Authors
Jacek Kubica
References (26)- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3): 245–252.
- Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016; 46(1): 7–14.
- Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208.
- Meine TJ, Roe MT, Chen AY, et al. CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049.
- Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013.
- Adamski P, Buszko K, Sikora J, et al. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Sci Rep. 2019; 9(1): 3924.
- Schoergenhofer C, Hobl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017; 117(8): 1582–1587.
- Buszko K, Kubica K, Hobl EL, et al. Pharmacokinetic modeling of morphine's effect on plasma concentrations of ticagrelor and its metabolite in healthy volunteers. Front Physiol. 2021; 12: 663170.
- Gue YX, Spinthakis N, Farag M, et al. Impact of preadmission morphine on reinfarction in patients with st-elevation myocardial infarction treated with percutaneous coronary intervention: a meta-analysis. Clin Pharmacol Ther. 2020; 108(1): 54–62.
- Liu Y, Kang S, Li X, et al. Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity. Cardiol J. 2021 [Epub ahead of print].
- Stiermaier T, Schaefer P, Meyer-Saraei R, et al. Impact of morphine treatment with and without metoclopramide coadministration on myocardial and microvascular injury in acute myocardial infarction: insights from the randomized MonAMI trial. J Am Heart Assoc. 2021; 10(9): e018881.
- Kubica A, Kosobucka A, Niezgoda P, et al. ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. BMJ Open. 2021; 11(3): e043330.
- Niezgoda P, Barańska MA, Sikora J, et al. Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor: NARCOTIC trial. Cardiol J. 2022; 29(3): 432–440.
- Franchi F, Rollini F, Park Y, et al. Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in Coronary artery disease patients treated with morphine. JACC Cardiovasc Interv. 2019; 12(16): 1538–1549.
- Niezgoda P, Barańska M, Adamski P, et al. Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study. Cardiol J. 2022; 29(2): 324–328.
- Iglesias JF, Valgimigli M, Carbone F, et al. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial. Cardiol J. 2022; 29(4): 591–600.
- Umińska JM, Ratajczak J, Pstrągowski K, et al. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. Cardiol J. 2022 [Epub ahead of print].
- Tomala MT, Trąbka-Zawicki A, Machnik A, et al. Ticagrelor effectively inhibits platelet aggregation in comatose survivors of cardiac arrest undergoing primary percutaneous coronary intervention treated with mild therapeutic hypothermia. Cardiol J. 2021 [Epub ahead of print].
- Ratajczak J, Łach P, Umińska JM, et al. Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter? Cardiol J. 2021; 28(2): 293–301.
- Umińska JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2020; 27(6): 780–788.
- Ostrowska M, Kubica J, Adamski P, et al. Stratified approaches to antiplatelet therapies based on platelet reactivity testing. Front Cardiovasc Med. 2019; 6: 176.
- Adamski P, Adamska U, Ostrowska M, et al. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018; 19(13): 1415–1425.
- Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.
- Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018; 19(12): 1389–1398.
- Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014; 30(5): 813–828.
